Citations 1
Global multi‐specialty clinician perspectives on the implementation of Alzheimer's disease blood biomarkers
Rodda, Joanne , Borelli, Wyllians Vendramini, Chabrashvili, Tinatin, Budelier, Melissa M. , Duran‐Aniotz, Claudia, Anderson, Leyla, Pereira, Ana Carolina, Castilhos, Raphael Machado, Kuchenbecker, Lindsey A. , Borelli, Wyllians Vendramini , DeMarco, Mari L. , Cawston, Erin E. , Chabrashvili, Tinatin, Duran‐Aniotz, Claudia , Udeh‐Momoh, Chinedu , Mielke, Michelle M. , Algeciras‐Schimnich, Alicia , Keshavan, Ashvini , Castilhos, Raphael Machado
Alzheimer's & Dementia | December 25, 2025 | Volume: 21 | Issue: S2 | Pages: No page available
Abstract Background Clinicians’ views on clinical readiness of Alzheimer's disease (AD) blood biomarkers (BBM) are not well understood. Method The Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment Biofluid‐Based Biomarkers Professional Interest Area conducted a survey to elicit clinician opinions on AD BBM implementation, including contexts of use, assay selection, reporting and result interpretation. Result Clinician respondents ( n = 212) practiced in Europe (56%), North America (24%), Caribbean and Central or South America (11%) and other continents (9%). Most respondents were medical doctors (80%) practicing in secondary or tertiary care (88%) (Table 1). For 56% of respondents, CSF AD biomarkers or amyloid PET were accessible, but 48% agreed and 52% disagreed with implementation of AD BBM in any clinical context (Table 2). Respondents emphasized the need for data from diverse populations and educational resources to support test interpretation. Conclusion Surveyed clinicians generally agreed with published appropriate use recommendations but were divided on AD BBM readiness for clinical use.